SQZ Pipeline

Diverse Pipeline Spanning Multiple Indications Across Broad Disease Areas

Platform

Cell Source/Cargo

Indication

Pre-Clinical

Phase 1/2

Oncology

B, T, NK, Monocytes
+ Peptide

Other Solid Tumors

B, T, NK, Monocytes
+ mRNA

H&N, Cervical, Anal Other Solid Tumors

RBC + Peptide + Adjuvant

Other Solid Tumors

Auto-
Immunity

RBC + Protein

Celiac Disease Type 1 Diabetes

Infectious Disease

B, T, NK, Monocytes
+ mRNA

Chronic Hepatitis B Virus

Oncology

B, T, NK, Monocytes + Peptide

Phase 1/2

Other Solid Tumors

Pre-Clinical

B, T, NK, Monocytes + mRNA

H&N, Cervical, Anal

Phase 1/2

Other Solid Tumors

Pre-Clinical

RBC + Peptide + Adjuvant

Phase 1/2

Other Solid Tumors

Pre-Clinical

Auto-Immunity

RBC + Protein

Celiac Disease

Pre-Clinical

Type 1 Diabetes

Pre-Clinical

Infectious Disease

B, T, NK, Monocytes + mRNA

Chronic Hepatitis B Virus

Pre-Clinical

The JDRF T1D Fund has invested in SQZ Biotech on multiple occasions to help progress the T1D program.